2 completed, 1 active not recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Active not recruiting 1 |
Follow Novoseven: new trials by email Literature Review of Novoseven trials Research Report on Novoseven
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial Recombinant Activated Factor VII (rFVIIa), Placebo - Intracerebral Hemorrhage | Phase 3 | Active not recruiting | Joseph Broderick, MD | 860 | 2021-12-03 | 2026-01-21 |
| Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency Eptacog alfa, biosimilar, Novoseven - Factor VII Deficiency | Phase 3 | Completed | AryoGen Pharmed Co. | 24 | 2017-03-01 | 2021-02-04 |
| Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation NovoSeven - Hemophilia A | Phase 3 | Completed | Medical University of Vienna | 2007-04-20 |
Cerebral Hemorrhage (1) · Factor VII Deficiency (1) · Hemophilia A (1)
AryoGen Pharmed Co. (1) · Joseph Broderick, MD (1) · Medical University of Vienna (1)
Austria (1) · Canada (1) · Germany (1) · Iran (1) · Japan (1) · Spain (1) · United Kingdom (1) · United States (1)
Joseph Broderick, MD (1) · Massimo Iacobelli, MD (1) · Sabine Eichinger, MD (1)
PMID 34427473, PMID 37870112, PMID 39654449, PMID 41653933
2019 (1), U01NS110772 (1)